411 related articles for article (PubMed ID: 19132197)
1. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
[TBL] [Abstract][Full Text] [Related]
2. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
4. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
5. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
6. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
9. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
10. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
14. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
Weerakkody GJ; Jakubowski JA; Brandt JT; Payne CD; Naganuma H; Winters KJ
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):205-12. PubMed ID: 17875947
[TBL] [Abstract][Full Text] [Related]
15. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
16. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
17. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
18. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.
Angiolillo DJ; Capranzano P; Desai B; Shoemaker SB; Charlton R; Zenni MM; Guzman LA; Bass TA
Thromb Res; 2009 Jul; 124(3):318-22. PubMed ID: 19012950
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
20. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]